New combo therapy takes on glioblastoma before surgery

NCT ID NCT05423210

Recruiting now Disease control Sponsor: Stony Brook University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial is testing whether combining a targeted radiation therapy with an immunotherapy drug (atezolizumab) before surgery can help fight glioblastoma, a fast-growing brain tumor. Twelve newly diagnosed patients will receive two weeks of treatment, then undergo surgery, followed by standard care plus atezolizumab. The study aims to see if this approach is safe and delays tumor progression.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Atezolizumab (Tecentriq) plus fractionated stereotactic radiotherapy
What this could lead to: If successful, this could point toward a new treatment approach that improves outcomes for glioblastoma patients.
What could go wrong: This is a very early, small pilot study with only 12 participants. The combination may not prove more effective than standard care, and there are risks of side effects from both radiation and immunotherapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA MULTIFORME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma glioma susceptibility 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA MULTIFORME

Contacts and locations

Locations

Stony Brook University Hospital
RECRUITING

Stony Brook, New York, 11794, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.